Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Annexon Inc's SEC filings provide detailed insights into the company's clinical development programs, financial position, and strategic direction as a biopharmaceutical firm targeting neurological disorders. For investors evaluating this clinical-stage biotech, several filing types offer particularly valuable information.
Quarterly reports on Form 10-Q and annual reports on Form 10-K detail Annexon's cash position and burn rate, critical metrics for a pre-revenue company funding operations through equity financing. These filings break down research and development expenses by program, revealing which therapeutic candidates receive the most investment. Clinical trial disclosures within these reports describe study designs, enrollment progress, and anticipated data readout timelines for programs in Huntington's disease, Alzheimer's disease, and geographic atrophy.
Form 8-K filings announce material events including clinical trial results, regulatory interactions, partnership agreements, and financing transactions. For a biotech like Annexon, these reports often contain the most market-moving information. Proxy statements on Form DEF 14A reveal executive compensation structures and board composition, showing how leadership incentives align with long-term development goals.
Form 4 insider transaction reports track when executives and directors buy or sell shares, providing signals about internal confidence in the company's prospects. Our AI-powered summaries highlight key disclosures from these complex documents, explaining what complement pathway biology revelations mean for Annexon's competitive position and translating dense clinical endpoint discussions into understandable terms. Access real-time filing updates and expert analysis to make informed decisions about this neurodegeneration-focused investment.
Annexon, Inc. director reports open-market stock purchase under a Rule 10b5-1 plan. On 12/01/2025, the reporting person bought 4,115 shares of Annexon common stock in a transaction coded as a purchase. The weighted average purchase price was $4.47 per share, with individual trades executed between $4.43 and $4.50.
After this transaction, the director beneficially owned 50,290 shares held directly. The filing notes that the trades were made pursuant to the director’s Rule 10b5-1 trading plan adopted on March 17, 2025, and the director has agreed to provide detailed trade information within the reported price range upon request.
Annexon, Inc. (ANNX)Muneer A. Satter through affiliated entities. On November 20, 2025, Alerce Medical Technology Partners, L.P. bought 400,000 shares of common stock at a weighted average price of $4.48. On November 21, 2025, Alerce Medical purchased an additional 422,613 shares at a weighted average price of $4.28. After these transactions, Satter is reported as beneficially owning 9,728,637 shares, held indirectly through a revocable trust, other trusts and entities, Satter Medical Technology Partners, L.P., and Alerce Medical, over which he has sole voting and dispositive power, while disclaiming beneficial ownership beyond his pecuniary interest.
Annexon, Inc. (ANNX) director reports sizable insider stock purchases. Over three consecutive days in November 2025, the reporting person, through Alerce Medical Technology Partners, L.P., bought 500,000 Annexon common shares on each of 11/17, 11/18, and 11/19.
The weighted average purchase prices were reported as $2.99, $3.18, and $3.94 for each respective day, with trades executed within stated price ranges. After these transactions, the reporting person beneficially owned 8,906,024 shares indirectly, including shares held in a revocable trust, various other trusts and entities, Satter Medical Technology Partners, L.P., and Alerce Medical, over which he has sole voting and dispositive power, subject to stated pecuniary interests.
Annexon, Inc. launched a primary offering of 25,096,153 shares of common stock and pre-funded warrants to purchase up to 3,750,000 shares, together with the shares issuable upon warrant exercise. The offering prices are $2.60 per share and $2.599 per pre-funded warrant, for gross proceeds of $74,996,247.80 and estimated net proceeds of about $69.9 million after fees and expenses.
The underwriters have a 30‑day option to buy up to 4,326,922 additional shares. Annexon plans to use proceeds to advance late‑stage programs, including tanruprubart in GBS and vonaprument in dry AMD with GA, and for working capital and general corporate purposes.
Pre-funded warrants have a $0.001 exercise price, do not expire, and include a 9.99% beneficial ownership limit (adjustable up to 19.99% with notice). Shares outstanding were 115,122,582 as of September 30, 2025, and are expected to be 140,218,735 immediately after this offering, assuming no exercise of pre-funded warrants.
Annexon, Inc. (ANNX) announced a primary offering of $75,000,000 of common stock, with the option for certain investors to purchase pre-funded warrants instead. The company also registered the shares issuable upon exercise of the pre-funded warrants. Underwriters have a 30‑day option to buy up to an additional $11,250,000 of common stock.
Pre-funded warrants will be sold at the share offering price minus $0.001 and have a $0.001 per share exercise price, are exercisable immediately, do not expire, and include a 9.99% Beneficial Ownership Limitation (adjustable up to 19.99% with 61 days’ notice). Annexon’s common stock trades on the Nasdaq Global Select Market under “ANNX”; the last reported sale price was $2.97 on November 11, 2025. Shares outstanding were 115,122,582 as of September 30, 2025; this is a baseline figure, not the amount being offered.
The company intends to use proceeds to advance its late‑stage neuroinflammation platform, led by global registrational programs tanruprubart in GBS and vonaprument in dry AMD with GA, and for working capital and other general corporate purposes. A 60‑day lock‑up applies, and sales under the existing 2024 ATM program are paused during this period.
Annexon, Inc. reported Q3 2025 results with a net loss of
Cash, cash equivalents and short‑term investments were
R&D increased as the company advanced tanruprubart (GBS) toward MAA/BLA packages and continued the vonaprument (GA) Phase 3 ARCHER II trial. The company raised
Annexon, Inc. (ANNX) furnished an update on its business by announcing certain financial results for the third quarter ended September 30, 2025. The company provided these details in a press release titled “Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones,” attached as Exhibit 99.1.
The information was furnished under Item 2.02 of a Form 8‑K and, as stated, is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference unless specifically noted.
Annexon (ANNX) filed a Form 4 reporting an insider purchase by a director. On 10/30/2025, the director bought 4,115 shares of common stock at a $3.17 weighted average price, with individual trades executed between $3.15 and $3.20. The transaction was made under a Rule 10b5-1 trading plan adopted on March 17, 2025. Following the trade, the director beneficially owns 46,175 shares, held directly.
William H. Carson, a director of Annexon, Inc. (ANNX), purchased 4,115 shares of the company’s common stock on 09/30/2025 at a weighted average price of $3.05 per share under a Rule 10b5-1 trading plan adopted on March 17, 2025. After the reported purchase, the filing shows the reporting person beneficially owned 42,060 shares. The filing states the trades executed at prices ranging from $3.035 to $3.08, and the reporting person offers to provide details of the per-trade quantities on request. The transaction was reported on a Form 4 as required for Section 16 reporting.
William H. Carson, a director of Annexon, Inc. (ANNX), purchased 4,115 shares of the company's common stock on 09/02/2025 at a weighted average price of $2.09 per share. The shares were bought under a Rule 10b5-1 trading plan adopted March 17, 2025, through multiple trades priced between $2.06 and $2.115.
Following the transaction, the reporting person beneficially owned 37,945 shares. The filing reports the purchase as a planned, rule-compliant acquisition rather than an opportunistic trade.
FAQ
What is the current stock price of Annexon (ANNX)?
What is the market cap of Annexon (ANNX)?
